Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401

Tenaya Therapeutics, Inc.

Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.
Cash and equivalents $78.1M as of June 30, 2026; runway extended through Q3 2027 including $10M Alnylam upfront.
Positive interim data from TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) trials: all evaluable patients showed improvements in hypertrophy and electrical stability.
Additional data and regulatory discussions on pivotal trial plans for TN-201 and TN-401 expected in Q4 2026.
Appointed Eric Hyllengren as CFO effective July 13, 2026; TN-301 Phase 2 trial expected to start 2H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.